Could a skin patch ease stomach pain in scleroderma?
NCT ID NCT06646913
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This pilot study tests whether a transcutaneous electrical nerve stimulation (TENS) device is acceptable and helpful for people with scleroderma who experience gastroparesis symptoms like bloating and distension. Participants use the device for 45 minutes twice daily after meals over four weeks, then track symptoms through diaries and questionnaires. The goal is to see if this non-invasive approach can ease digestive discomfort and whether people can stick with it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Transcutaneous electrical nerve stimulation (TENS) device
- What this could lead to
- If it works, this could offer a drug-free, at-home option to ease bloating and discomfort in people with scleroderma-related gastroparesis.
- What could go wrong
- This is a small pilot study focused on whether people will use the device, not proof of effectiveness. Results may not apply broadly, and symptom relief is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROPARESIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan
Ann Arbor, Michigan, 48912, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Can a new pill ease the hardening skin of systemic sclerosis?
- Could a botox shot in the gut ease Kids' chronic vomiting?
- A drug after transplant may stop scleroderma from coming back
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.